UK markets closed

Zynerba Pharmaceuticals, Inc. (0M40.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.4720-0.0500 (-1.98%)
At close: 02:41PM GMT
Sign in to post a message.
  • j
    john
    I just don't understand why anyone would be selling at this low price? It's just too low to make any profits! So, why the continued selloff? I'm in it for the long haul as I would expect most of the people who follow this stock are, too.
  • H
    Hervelo
    Wonderfull, ZGNX acquired ... after GWPH was acquired ...once ZYNE gets APPROVAL and starts to sell something it will be a target !!!!
  • H
    Hervelo
    We are at a 7 years low ...really ... A once in a life opportunity or they will go BK ? I am inclined to see as an opportunity to add some ...
  • J
    James
    Just when I thought this couldn't go lower. THUD. It drops to a new low. Come on management do something!!
  • e
    edebear
    “Committing to a Phase 3 development program for patients with autism spectrum disorder is a key step in the advancement of a new treatment option for patients who have high unmet medical needs and limited FDA approved treatment options,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “Data from our ASD clinical development program to date are compelling and, with a clear regulatory path toward potential approval, we are excited to move forward with this program.”

    Anido added, “In addition, we are making good progress towards completing enrollment in the INSPIRE trial for patients with 22q11.2 deletion syndrome and expect to have topline results mid-year 2022. Putting resources behind a second indication beyond FXS and completing the INSPIRE trial is consistent with our mission of being a leader in rare and near-rare neuropsychiatric disorders, including FXS, ASD and 22q.”
  • J
    John
    I’m about to buy more, seems like when I do, it always goes down. Just want to let everyone know ahead of time. Buying tomorrow. Smh.
  • T
    Trond
    In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $9.00. The company’s shares closed last Wednesday at $2.80.
  • e
    edebear
    The Company received written scientific advice from the European Medicines Agency (EMA) providing clarity and guidance on the clinical and regulatory requirements for the submission of a marketing authorization application (MAA) in the European Union (EU) for Zygel for the treatment of behavioral symptoms associated with FXS. Based on the EMA’s scientific advice, the Company believes that the successful completion of the current development program for Zygel in FXS will satisfy the requirements of an MAA in the EU.
  • e
    edebear
    Last September it was announced that RECONNECT will be an 18-week trial that is expected to enroll approximately 200 children and adolescents, aged three through 17 years, at approximately 25 clinical sites in the United States, Australia, the UK and Ireland. It's about time management started to update us with some results. Shareholders need to have some kind of status on data being accumulated.
  • s
    steven
    In that CNN article a woman got her son back from Autism cause of CBD...what the H is going on with our Management team
  • s
    steven
    has there been any insider buying by management..here at $2..or do they think its a lost cause
  • j
    john
    sure is very quiet on this board and with ZYNE! What is going on with their trials and FDA approvals? Any news?
  • J
    James
    Man this stock is a dud! Can't this company do anything to produce some shareholder value in the medical CBD treatment space! Terrible investment!
  • s
    steven
    New 52 week low...again...what is mgmt doing..should we vote them out
  • T
    Trond
    Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders.

    With cash and equivalents at $75.6 million as of September 30, 2021, Zynerba believes its funding would be sufficient until H2 2023.

    Good news.
  • e
    edebear
    After watching CNN's special report "Weeds 6 Cannabis and Autism" I more convinced than ever of the importance of Zynerba's work. While only showcasing a few examples of the positive results cannabis can have with autistic children, the report still illustrated the wider potential of cannaboids in the treatment of autism.
  • A
    Anonymous
    When all of the data comes together this will be a huge winner for both patients and investors.
  • S
    Serge
    Time to buy